| Sector |
Capital Goods
|
Compare with Sector peers |
| Industry |
Engineering - Industrial Equipments
|
Compare with Industry peers |
| Website | http://www.mazdalimited.com | |
| Market Cap | 221.22 Cr. | |
| Enterprise Value(EV) | 216.47 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 53.04 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 10.41 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 30.08 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 409.56 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.35 | Calculated using Price: 552.35 |
| Dividend Yield | 2.19 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.40 Cr. | 4,005,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Mazda Ltd. was established in 1977, as a small unit in western India with the objective of manufacturing automated valve packages. Over the years, it gradually expanded its operations and marketing, taking care to instil the highest levels of quality in all its products, with near-obsessive attention to details and customers satisfaction. Over the years, its quest for further growth led to an equity participation and technical collaboration with market leaders Croll-Reynolds Inc., USA, in the field of vacuum systems and air pollution control equipment. In time, the company extended into a second international collaboration with Germany-based Kauer Engineering for Turbine Bypass Valves, followed by a consolidation of its technological strengths to diversify into Evaporators and Crystallisers. Today two decades down the road, Mazda Ltd has come long way. It has clearly established itself, in domestic and global markets, as a pioneer and leader in its chosen fields, offering the finest “in specialised, high value” products. In its new growth phase, the company is now radically diversifying into the high-potential sunrise industry, Biotechnology in the field of carbohydrates, rare sugars and miscellaneous bio-chemicals. Different divisions of the company: Engineering Division It specialises in supplying equipments to various industries like power, fertilizers, chemicals and bulk drugs industries. It also caters to the needs of refineries, sugar and food, pulp and paper and others. Mazda Limited has built a strategic alliance with Croll-Reynolds Inc. USA (C-R), who is a major shareholder in Mazda Controls. Croll-Reynolds has shared a substantial amount of technology with Mazda. At its facilities in Ahmedabad, Mazda and Croll-Reynolds work together to design, manufacture and test high quality equipments for sale to all the regions of the world. Biochemical Division Special Sugars- Glycals are sophisticated Chiral building blocks that can be used in chemical, enzymatic and combinatorial synthesis of natural and unnatural complex carbohydrates, oligosaccharide and glycoconjugate targets for advanced research in the pharmaceutical and biotechnology industries. Carbohydrates are key elements in various molecular signaling and recognition process at the cellular level in all living organisms. They also play central role in human immune system, and are important in the onset of illness and disease. Product range of the company includes:
|
||
Company Profile
Mazda Ltd. was established in 1977, as a small unit in western India with the objective of manufacturing automated valve packages. Over the years, it gradually expanded its operations and marketing, taking care to instil the highest levels of quality in all its products, with near-obsessive attention to details and customers satisfaction.
Over the years, its quest for further growth led to an equity participation and technical collaboration with market leaders Croll-Reynolds Inc., USA, in the field of vacuum systems and air pollution control equipment.
In time, the company extended into a second international collaboration with Germany-based Kauer Engineering for Turbine Bypass Valves, followed by a consolidation of its technological strengths to diversify into Evaporators and Crystallisers.
Today two decades down the road, Mazda Ltd has come long way. It has clearly established itself, in domestic and global markets, as a pioneer and leader in its chosen fields, offering the finest “in specialised, high value” products.
In its new growth phase, the company is now radically diversifying into the high-potential sunrise industry, Biotechnology in the field of carbohydrates, rare sugars and miscellaneous bio-chemicals.
Different divisions of the company:
Engineering Division
It specialises in supplying equipments to various industries like power, fertilizers, chemicals and bulk drugs industries. It also caters to the needs of refineries, sugar and food, pulp and paper and others. Mazda Limited has built a strategic alliance with Croll-Reynolds Inc. USA (C-R), who is a major shareholder in Mazda Controls. Croll-Reynolds has shared a substantial amount of technology with Mazda. At its facilities in Ahmedabad, Mazda and Croll-Reynolds work together to design, manufacture and test high quality equipments for sale to all the regions of the world.
Biochemical Division
Special Sugars- Glycals are sophisticated Chiral building blocks that can be used in chemical, enzymatic and combinatorial synthesis of natural and unnatural complex carbohydrates, oligosaccharide and glycoconjugate targets for advanced research in the pharmaceutical and biotechnology industries. Carbohydrates are key elements in various molecular signaling and recognition process at the cellular level in all living organisms. They also play central role in human immune system, and are important in the onset of illness and disease.
Product range of the company includes:
| 1 Day |
|
-3.05% |
| 1 Week |
|
+12.27% |
| 1 Month |
|
+5.11% |
| 3 Month |
|
+13.49% |
| 6 Month |
|
-13.24% |
| 1 Year |
|
-3.77% |
| 2 Year |
|
+124.62% |
| 5 Year |
|
+69.88% |
| 10 Year |
|
+514.40% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 17.46 | 12.90 | 12.90 | 12.65 | 11.88 | 8.49 | 10.88 | 12.51 | 11.69 | |
| Return on Capital Employed (%) | 26.70 | 19.01 | 18.31 | 18.23 | 13.92 | 12.14 | 14.64 | 17.40 | 16.25 | |
| Return on Assets (%) | 13.39 | 9.66 | 9.39 | 9.43 | 9.46 | 7.06 | 8.70 | 9.78 | 9.60 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 76 | 83 | 91 | 100 | 118 | 125 | 134 | 132 | 147 | 164 | |
| Non Curr. Liab. | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | |
| Curr. Liab. | 18 | 31 | 30 | 30 | 20 | 23 | 35 | 32 | 23 | 25 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 96 | 116 | 123 | 132 | 141 | 151 | 173 | 167 | 173 | 192 | |
| Non Curr. Assets | 25 | 25 | 26 | 31 | 45 | 42 | 50 | 64 | 69 | 79 | |
| Curr. Assets | 71 | 91 | 96 | 101 | 96 | 109 | 123 | 103 | 104 | 113 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 96 | 116 | 123 | 132 | 141 | 151 | 173 | 167 | 173 | 192 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 121 | 103 | 118 | 122 | 110 | 107 | 139 | 180 | 152 | 165 | |
| Other Income | 2 | 2 | 1 | 2 | 5 | 4 | 3 | 2 | 2 | 3 | |
| Total Income | 123 | 105 | 119 | 124 | 115 | 111 | 142 | 181 | 155 | 168 | |
| Total Expenditure | -102 | -88 | -101 | -104 | -97 | -93 | -120 | -155 | -129 | -138 | |
| PBIDT | 21 | 17 | 19 | 20 | 18 | 18 | 22 | 27 | 26 | 31 | |
| Interest | -1 | -1 | -1 | -1 | 0 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -2 | |
| Taxation | -6 | -5 | -5 | -5 | -2 | -4 | -4 | -6 | -6 | -6 | |
| Exceptional Items | 0 | 0 | 0 | ||||||||
| PAT | 12 | 10 | 11 | 12 | 13 | 10 | 14 | 17 | 16 | 21 | |
| Adjusted EPS | 29 | 24 | 26 | 28 | 30 | 24 | 33 | 42 | 41 | 53 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 11 | 12 | 16 | 17 | 7 | 14 | -5 | 22 | 20 | |
| Cash Fr. Inv. | -3 | -7 | -11 | -9 | -17 | -10 | -7 | 10 | 4 | -20 | |
| Cash Fr. Finan. | -1 | -1 | -1 | -4 | -4 | -4 | -4 | -9 | -19 | -2 | |
| Net Change | -2 | 3 | 0 | 3 | -4 | -7 | 3 | -4 | 7 | -2 | |
| Cash & Cash Eqvt | 3 | 6 | 6 | 8 | 5 | 3 | 6 | 2 | 9 | 7 |
|
Mon, 23 May 2022
Outcome Of Board Meeting Held On 23Rd May 2022 Pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 at the Board Meeting held today the Board of Directors has inter alia approved the following:1. Approved and taken on record Audited Financial Results (Standalone) for the quarter and year ended on 31st March 2022 along with Auditors Report on Audited Financial Statements. Pursuant to regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby declare that the Statutory Auditor of the company Mayank Shah & Associates (Firm Registration No. 106109W) has issued the Audit Report on Standalone financial results for the quarter and financial year ended on 31st March 2022 is with unmodified opinion. |
|
Mon, 23 May 2022
Corporate Action-Board approves Dividend Pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 at the Board Meeting held today the Board of Directors has inter alia approved the following:2. Recommended a dividend of (121%) Rs. 12.10 per equity share of face value of Rs. 10/- each for the financial year ended 31st March 2022 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
|
Mon, 23 May 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On 23Rd May 2022 Pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 at the Board Meeting held today the Board of Directors has inter alia approved the following:1. Approved and taken on record Audited Financial Results (Standalone) for the quarter and year ended on 31st March 2022 along with Auditors Report.2. Recommended a dividend of (121%) Rs. 12.10 per equity share of face value of Rs. 10/- each for the financial year ended 31st March 2022 subject to the approval of the shareholders at the ensuing Annual General Meeting. 3. The term of M/s. Mayank Shah & Associates Chartered Accountants will end at the conclusion of the ensuing 32nd AGM of the Company. The Board of Directors have recommended that M/s. Mayank Shah & Associates Chartered Accountants be re-appointed as the Statutory Auditors of the Company. |
| Wed, 25 May 2022 |
Opening at High
|
Closing Below Previous Low
|
High Increase 1 Month
|
High Increase 3 Months
|
High Increase 2 Years
|
Equities
M.F.
Sectors